Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
48
ORYZF Quote, Financials, Valuation and Earnings
Last price:
$3.34
Seasonality move
:
13.42%
Day range:
$3.34 - $3.34
52-week range:
$3.03 - $4.38
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
440.67x
P/B ratio:
2.09x
Volume:
56
Avg. volume:
129
1-year change:
7.74%
Market cap:
$258.9M
Revenue:
--
EPS (TTM):
-$0.04
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Oryzon Genomics SA has -- downside to fair value with a price target of -- per share.
ORYZF vs. S&P 500
-
Over the past 5 trading days, Oryzon Genomics SA has underperformed the S&P 500 by -3.25% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Oryzon Genomics SA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Oryzon Genomics SA revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Oryzon Genomics SA reported revenues of --.
Earnings Growth
-
Oryzon Genomics SA has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Oryzon Genomics SA reported earnings per share of -$0.02.
Enterprise value:
239.6M
EV / Invested capital:
--
Price / LTM sales:
440.67x
EV / EBIT:
474.07x
EV / Revenue:
464.69x
PEG ratio (5yr expected):
-59.65x
EV / Free cash flow:
-7.08x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
474.07x
Gross Profit (TTM):
-$151K
Return On Assets:
-1.94%
Net Income Margin (TTM):
--
Return On Equity:
-2.63%
Return On Invested Capital:
-2.33%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$165.3K | -$159.8K | -$151K | -$39K | -$36.7K | |
| Operating Income | -$5.1M | -$4.8M | -$7.3M | -$1.1M | -$2.3M | |
| EBITDA | -$4.9M | -$4.7M | -$7.1M | -$1.1M | -$2.3M | |
| Diluted EPS | -$0.06 | -$0.06 | -$0.04 | -$0.02 | -$0.02 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $26.9M | $15.8M | $9.1M | $36M | |
| Total Assets | -- | $110.7M | $118.1M | $113.7M | $169.7M | |
| Current Liabilities | -- | $20M | $18.1M | $12.2M | $18.5M | |
| Total Liabilities | -- | $33.2M | $27.8M | $22.4M | $31.3M | |
| Total Equity | -- | $70.9M | $83M | $83.9M | $123.8M | |
| Total Debt | -- | $20.5M | $9M | $8.4M | $8.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -$4M | -$1.2M | |
| Cash From Investing | -- | -- | -- | -$4.7M | -$4.8M | |
| Cash From Financing | -- | -- | -- | $6.4M | $34.9M | |
| Free Cash Flow | -$36.3M | -$36.4M | -$33M | -$8.8M | -$6M | |
ORYZF
Sector
Market Cap
$258.9M
$23.9M
Price % of 52-Week High
76.34%
47.44%
Dividend Yield
0%
0%
Shareholder Yield
0.03%
-1.9%
1-Year Price Total Return
7.74%
-18.29%
Beta (5-Year)
0.334
0.513
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.34
200-day SMA
Sell
Level
$3.41
Bollinger Bands (100)
Sell
Level
3.31 - 3.55
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$3.30
Relative Strength Index (RSI14)
Sell
Level
37.48
ADX Line
Buy
Level
58.91
Williams %R
Sell
Level
0
50-day SMA
Sell
Level
$3.46
MACD (12, 26)
Buy
Level
0.88
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Neutral
Level
800
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.7693)
Buy
CA Score
(Annual)
Level (0.3723)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-0.0615)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. It focuses on epigenetics in various therapeutic indications, with a special emphasis on oncology and neurodegenerative disease. The firm's product pipelines include Iadademstat and Vafidemstat. The company was founded by Carlos Manuel Buesa Arjol and Tamara Maes on June 2, 2000 and is headquartered in Barcelona, Spain.
Stock Forecast FAQ
In the current month, ORYZF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ORYZF average analyst price target in the past 3 months is --.
-
Where Will Oryzon Genomics SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Oryzon Genomics SA share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Oryzon Genomics SA?
Analysts are divided on their view about Oryzon Genomics SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Oryzon Genomics SA is a Sell and believe this share price will rise from its current level to --.
-
What Is Oryzon Genomics SA's Price Target?
The price target for Oryzon Genomics SA over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ORYZF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Oryzon Genomics SA is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ORYZF?
You can purchase shares of Oryzon Genomics SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Oryzon Genomics SA shares.
-
What Is The Oryzon Genomics SA Share Price Today?
Oryzon Genomics SA was last trading at $3.34 per share. This represents the most recent stock quote for Oryzon Genomics SA. Yesterday, Oryzon Genomics SA closed at $3.34 per share.
-
How To Buy Oryzon Genomics SA Stock Online?
In order to purchase Oryzon Genomics SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ORYZF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ORYZF
Sector
P/E ratio
--
21.37x
PEG ratio
-59.65x
-0.01x
P/B ratio
2.09x
1.72x
Price / LTM sales
440.67x
1.44x
Growth Metrics
ORYZF
Sector
Revenue growth
--
3.44%
Earnings growth
12.17%
14.97%
Revenue (5-year growth)
--
6.27%
Earnings forecast
--
-$0.22
Profitability
ORYZF
Sector
Profitability FY 2025
-$151.1K
$2.4M
Return on invested capital
-2.33%
-33.43%
Return on assets
-1.94%
-29.45%
Return on equity
-2.63%
-40.29%
Earnings Date
Last Earnings Date
Apr
4
Next Earnings Date
Apr
4
Estimated Next Earnings Date
Jul
4
Balance Sheet
ORYZF
Sector
Total cash
$33.3M
$25.6M
Short term investments
--
$22.7M
Total assets
$169.7M
$70.4M
Long term debt
$8.6M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
